Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio, Inc. - Common Stock (NQ:ACET)

0.6936 -0.0251 (-3.49%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Adicet Bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
70 Biggest Movers From Friday
Gainers Avadel Pharmaceuticals plc (NASDAQ: AVDL) shares climbed 133.6% to close at $2.50 on Friday. Avadel Pharmaceuticals shares dipped 68% on Thursday after announcing new FDA request for... 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Adicet Bio, Inc. (NASDAQ: ACET) rose 16% to $11.90 in pre-market trading after reporting positive clinical update from ADI-001 Phase 1 Trial in relapsed/refractory Non-Hodgkin’s Lymphoma. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers 
Via Benzinga
Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports First Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Presents Preclinical Data at the ISCT Annual Meeting Highlighting Potential Advantages of the Non-Gene-Edited Approach for its Investigational Allogeneic Gamma Delta CAR T Cell Therapy Targeting CD20 for B Cell Malignancies
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Announces Oral Presentation of Updated ADI-001 Phase 1 Data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Receives FDA Fast Track Designation for Lead Candidate ADI-001
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Participate in Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Where Adicet Bio Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on Adicet Bio (NASDAQ:ACET) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
Adicet Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress
From Adicet Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2022
Upgrades According to Janney Montgomery Scott, the prior rating for Wintrust Financial Corp (NASDAQ:WTFC) was changed from Neutral to Buy. Wintrust Finl earned $1.58 in the fourth... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 4, 2022
Upgrades According to Susquehanna, the prior rating for Knight-Swift Transportation Holdings Inc (NYSE:KNX) was changed from Neutral to Positive. Knight-Swift earned $1.61 in the... 
Via Benzinga
Adicet Bio to Participate in Guggenheim 2022 Oncology Conference
From Adicet Bio, Inc.
Via Business Wire
4 Stocks Insiders Are Buying
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, t... 
Via Benzinga
Adicet Bio Raises $87M Via Equity To Fund Development Of Non-Hodgkin's Lymphoma Candidate
Adicet Bio Inc (NASDAQ: ACET) priced an underwritten public offering of 6.25 million shares at $14.00 per share, raising gross proceeds of $87.5 million. The offer... 
Via Benzinga
The Daily Biotech Pulse: Valneva Strikes Deal To Supply COVID Vaccine to Bahrain, TherapeuticsMD & Amneal Settle Patent Lawsuit, Reata Awaits Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus EyePoint Announces Commercialization Agreement For Dexycu To Treat Post-... 
Via Benzinga
Topics Intellectual Property Lawsuit
Exposures Financial Intellectual Property Legal
60 Biggest Movers From Yesterday
Gainers Insignia Systems, Inc. (NASDAQ: ISIG) shares jumped 200.4% to close at $15.05 on Monday after the company announced the commencement of a formal process to explore... 
Via Benzinga
Mid-Afternoon Market Update: Dow Jumps 700 Points; Del Taco Restaurants Shares Spike Higher
Toward the end of trading Monday, the Dow traded up 2.11% to 35,308.84 while the NASDAQ rose 1.24% to 15,272.25. The S&P also rose, gaining 1.51% to 4,607.08. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Adicet Bio (NASDAQ:ACET) shares i... 
Via Benzinga
Mid-Day Market Update: Crude Oil Rises 3%; Aeglea BioTherapeutics Shares Plunge
Midway through trading Monday, the Dow traded up 1.94% to 35,251.31 while the NASDAQ rose 0.55% to 15,168.35. The S&P also rose, gaining 1.20% to 4,592.83. The U.S. has the... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
36 Stocks Moving In Monday's Mid-Day Session
Gainers Del Taco Restaurants, Inc. (NASDAQ: TACO) shares jumped 64.6% to $12.40. Jack In The Box Inc (NASDAQ: JACK) agreed to acquire Del Taco Restaurants for $12.51 per share... 
Via Benzinga
Why Adicet Bio Stock Is Skyrocketing Today
The company reported positive interim results from a phase 1 study. 
Via The Motley Fool
Mid-Morning Market Update: Markets Mostly Higher; Science Applications International Posts Upbeat Earnings
Following the market opening Monday, the Dow traded up 1.35% to 35,048.01 while the NASDAQ fell 0.17% to 15,059.43. The S&P also rose, gaining 0.59% to 4,565.21. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
Adicet Stock Rallies After Early Responses For Off-The-Shelf Drug In B-cell Non-Hodgkin's Lymphoma
Adicet Bio Inc (NASDAQ: ACET) has announced positive interim data from its dose-escalation Phase 1 study evaluating ADI-001 for B-cell Non-Hodgkin's Lymphoma.... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.